CN102123707A - 用于经皮介入心导管插入术的达比加群 - Google Patents

用于经皮介入心导管插入术的达比加群 Download PDF

Info

Publication number
CN102123707A
CN102123707A CN2009801318235A CN200980131823A CN102123707A CN 102123707 A CN102123707 A CN 102123707A CN 2009801318235 A CN2009801318235 A CN 2009801318235A CN 200980131823 A CN200980131823 A CN 200980131823A CN 102123707 A CN102123707 A CN 102123707A
Authority
CN
China
Prior art keywords
formula
compound
pharmaceutically acceptable
maleate
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801318235A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·A·赖利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41258283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102123707(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN102123707A publication Critical patent/CN102123707A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
CN2009801318235A 2008-08-19 2009-08-17 用于经皮介入心导管插入术的达比加群 Pending CN102123707A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19
US61/090,018 2008-08-19
PCT/EP2009/060592 WO2010020602A1 (en) 2008-08-19 2009-08-17 Dabigatran for percutaneous interventional cardiac catheterisation

Publications (1)

Publication Number Publication Date
CN102123707A true CN102123707A (zh) 2011-07-13

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801318235A Pending CN102123707A (zh) 2008-08-19 2009-08-17 用于经皮介入心导管插入术的达比加群

Country Status (19)

Country Link
US (1) US20110301201A1 (cg-RX-API-DMAC7.html)
EP (1) EP2328580A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012500245A (cg-RX-API-DMAC7.html)
KR (1) KR20110044230A (cg-RX-API-DMAC7.html)
CN (1) CN102123707A (cg-RX-API-DMAC7.html)
AR (1) AR073077A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009284217A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917507A2 (cg-RX-API-DMAC7.html)
CA (1) CA2734794A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011000361A1 (cg-RX-API-DMAC7.html)
CO (1) CO6290686A2 (cg-RX-API-DMAC7.html)
EA (1) EA201100358A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11010825A (cg-RX-API-DMAC7.html)
IL (1) IL210005A0 (cg-RX-API-DMAC7.html)
MA (1) MA32563B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001612A (cg-RX-API-DMAC7.html)
NZ (1) NZ591108A (cg-RX-API-DMAC7.html)
TW (1) TW201022235A (cg-RX-API-DMAC7.html)
WO (1) WO2010020602A1 (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391250A (zh) * 2011-08-29 2012-03-28 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420985A (zh) * 2012-05-24 2013-12-04 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982A (zh) * 2012-05-24 2013-12-04 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420984A (zh) * 2012-05-24 2013-12-04 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559A (zh) * 2012-07-05 2014-01-22 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779A (zh) * 2012-07-13 2014-01-29 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358368A1 (en) 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
CA2791561A1 (en) * 2010-03-01 2011-09-09 Ratiopharm Gmbh Dabigatran etexilate-containing oral pharmaceutical composition
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
IN2015DN02601A (cg-RX-API-DMAC7.html) * 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485094B2 (de) * 2002-03-07 2020-03-25 Boehringer Ingelheim International GmbH Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze
JP2008517974A (ja) * 2004-10-25 2008-05-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用
CA2657270A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New paediatric indications for direct thrombin inhibitors
JP2009543842A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓血管分野における直接トロンビン阻害薬のための新規適応
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391250A (zh) * 2011-08-29 2012-03-28 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420985A (zh) * 2012-05-24 2013-12-04 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982A (zh) * 2012-05-24 2013-12-04 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420984A (zh) * 2012-05-24 2013-12-04 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559A (zh) * 2012-07-05 2014-01-22 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779A (zh) * 2012-07-13 2014-01-29 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途

Also Published As

Publication number Publication date
KR20110044230A (ko) 2011-04-28
AU2009284217A1 (en) 2010-02-25
AR073077A1 (es) 2010-10-13
JP2012500245A (ja) 2012-01-05
MA32563B1 (fr) 2011-08-01
TW201022235A (en) 2010-06-16
IL210005A0 (en) 2011-02-28
ECSP11010825A (es) 2011-03-31
WO2010020602A1 (en) 2010-02-25
CL2011000361A1 (es) 2011-06-17
EA201100358A1 (ru) 2011-10-31
MX2011001612A (es) 2011-03-04
BRPI0917507A2 (pt) 2015-11-17
EP2328580A1 (en) 2011-06-08
NZ591108A (en) 2012-11-30
CA2734794A1 (en) 2010-02-25
US20110301201A1 (en) 2011-12-08
CO6290686A2 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
TW201022235A (en) New use of dabigatran
CN100528157C (zh) 3-[(2-{[4-(己氧羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯及其盐的口服施用的投药剂型
RU2072840C1 (ru) Твердая лекарственная форма пролонгированного действия для лечения сердечно-сосудистых заболеваний
US20180221359A1 (en) Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
CN101980697A (zh) 制备口服给药的达比加群制剂的方法
US20110306640A1 (en) Dabigatran in tumour therapy
US20130109722A1 (en) Use of dabigatran etexilate for treating patients with pulmonary hypertension
US20120142703A1 (en) New combination therapy in treatment of oncological and fibrotic diseases
JP2007518755A (ja) モノアミン神経伝達物質再取り込み阻害剤及びn−メチル−d−アスパラギン酸(nmda)受容体アンタゴニストを含む医薬組成物
CN111150714A (zh) 一种甲磺酸达比加群酯固体药物制剂及其制备方法
JP2003500348A (ja) 多粒子状制御放出選択的セロトニン再吸収阻害剤製剤
TW201124143A (en) Emergency interventions of active charcoal with dabigatran etexilate overdosing
CN101632668A (zh) 口服药物组合物
HK1154499A (en) Dabigatran for percutaneous interventional cardiac catheterisation
JP2002518330A (ja) 処置方法
HK1078792B (en) Form of presentation for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester to be administered orally
HK1135337A (en) Orally administered pharmaceutical composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154499

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110713

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1154499

Country of ref document: HK